Table 2.
Associations by univariate logistic regression analyses of demographic factors, IV drug use duration, viral coinfection status, and CCL3L1 or CCR5 genotype with HIV or HCV serostatus
| Outcome: HIV serostatus | Outcome: HCV | |
|---|---|---|
| Covariate |
OR; 95% CI; P |
OR; 95% CI; P |
| Gender | ||
| Male* | 1.0 | 1.0 |
| Female | 1.08; 0.60–1.94; 0.797 | 0.52; 0.27–0.99; 0.0455 |
| Age | ||
| <26 years* | 1.0 | 1.0 |
| ≥26 years | 1.10, 0.70–1.72; 0.691 | 1.18; 0.69–2.02; 0.5378 |
| HCV status | ||
| HCV−* | 1.0 | |
| HCV+ | 3.01; 1.83–4.96; 1.45×10−5 | |
| HIV status | ||
| HIV−* | 1.0 | |
| HIV+ | 3.01; 1.83–4.96; 1.45×10−5 | |
| HBV status | ||
| HBV−* | 1.0 | 1.0 |
| HBV+ | 5.10; 2.42–10.75; 1.85×10−5 | 3.57; 1.38–9.25; 0.0088 |
| IV drug use duration | ||
| Yearsb | 1.08; 1.01–1.15; 0.025 | 1.24; 1.13–1.36; 1.10×10−5 |
| CCL3L1 copy number | ||
| 0–2* | 1.0 | 1.0 |
| 3–6 | 0.49; 0.29–0.81; 0.006 | 1.15; 0.62–2.12; 0.6558 |
| CCR5 genotype | ||
| wt/wt* | 1.0 | 1.0 |
| wt/Δ32 or | 0.81; 0.49–1.33; 0.398 | 1.47; 0.78–2.78; 0.2363 |
*
NOTE., reference group; OR, odds ratio; CI, confidence interval; P, significance value.
a
Years was categorized as a continuous variable in full-years, and data reflects an increase in OR with each additional year of IV drug use.